Impact of Preoperative Liver Function on Short-Term HeartMate 3 Outcomes

Abstract

Although left ventricular assist device (LVAD) therapy is associated with improved survival, the impact of preoperative liver function on short-term outcomes is unclear. We conducted a retrospective review of all primary HeartMate 3 LVAD implants at a single center. Composite metrics of hepatic function including the model for end-stage liver disease (MELD), the MELD with sodium, and the MELD excluding international normalized ratio (MELD-XI) were evaluated. Receiver operator characteristic curves were compared to determine which equation was most predictive of 1-year survival. Primary stratification was based on MELD-XI tertiles. Secondary stratification was based on hypoalbuminemia (<3.0 mg/100 ml). A total of 94 patients underwent primary LVAD implantation from 2017 to 2022. MELD-XI and hypoalbuminemia were most associated with 1-year outcomes. When stratified by MELD tertiles, higher MELD was strongly associated with decreased 30 days (100.00% vs 100.00% vs 90.32%, p=0.04), 1-year (93.00% vs 93.32% vs 69.79%, p=0.01), and 2-year survival (93.00% vs 83.21% vs 69.79%, p=0.04). In addition, while hypoalbuminemia was associated with similar 30 days (97.87% vs 95.74%, p=0.56) survival, it was associated with a significant decrease in 1-year (92.93% vs 77.92%, p=0.03) and 2-year survival (92.93% vs 68.89%, p <0.01). These results persisted on multivariable analysis for both MELD-XI score (p=0.04) and hypoalbuminemia (p=0.04). In conclusion, this is the first study to demonstrate that preoperative MELD-XI score and serum albumin levels are associated with short-term HeartMate 3 outcomes.